Literature DB >> 33539624

In Reply.

Mairéad Geraldine McNamara1, Juan W Valle1.   

Abstract

Year:  2021        PMID： 33539624      PMCID： PMC8100572          DOI： 10.1002/onco.13704

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  10 in total

1.  In Regard to "A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)".

Authors:  Angela Dalia Ricci; Alessandro Rizzo; Giovanni Brandi
Journal:  Oncologist       Date:  2021-02-15

2.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

3.  Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.

Authors:  Kristina Lindemann; Bo Gao; Cristina Mapagu; Sian Fereday; Catherine Emmanuel; Kathryn Alsop; Nadia Traficante; Paul R Harnett; David D L Bowtell; Anna deFazio
Journal:  Gynecol Oncol       Date:  2018-05-26       Impact factor: 5.482

Review 4.  Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.

Authors:  Thomas J Smith; Kari Bohlke; Gary H Lyman; Kenneth R Carson; Jeffrey Crawford; Scott J Cross; John M Goldberg; James L Khatcheressian; Natasha B Leighl; Cheryl L Perkins; George Somlo; James L Wade; Antoinette J Wozniak; James O Armitage
Journal:  J Clin Oncol       Date:  2015-07-13       Impact factor: 44.544

5.  A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08).

Authors:  Mairéad G McNamara; John Bridgewater; Daniel H Palmer; Olusola Faluyi; Harpreet Wasan; Alkesh Patel; William D Ryder; Safia Barber; Chathunissa Gnanaranjan; Essam Ghazaly; T R Jeff Evans; Juan W Valle
Journal:  Oncologist       Date:  2020-12-03

6.  Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.

Authors:  Ghassan K Abou-Alfa; Vaibhav Sahai; Antoine Hollebecque; Gina Vaccaro; Davide Melisi; Raed Al-Rajabi; Andrew S Paulson; Mitesh J Borad; David Gallinson; Adrian G Murphy; Do-Youn Oh; Efrat Dotan; Daniel V Catenacci; Eric Van Cutsem; Tao Ji; Christine F Lihou; Huiling Zhen; Luis Féliz; Arndt Vogel
Journal:  Lancet Oncol       Date:  2020-03-20       Impact factor: 41.316

7.  Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

Authors:  Ghassan K Abou-Alfa; Teresa Macarulla; Milind M Javle; Robin K Kelley; Sam J Lubner; Jorge Adeva; James M Cleary; Daniel V Catenacci; Mitesh J Borad; John Bridgewater; William P Harris; Adrian G Murphy; Do-Youn Oh; Jonathan Whisenant; Maeve A Lowery; Lipika Goyal; Rachna T Shroff; Anthony B El-Khoueiry; Bin Fan; Bin Wu; Christina X Chamberlain; Liewen Jiang; Camelia Gliser; Shuchi S Pandya; Juan W Valle; Andrew X Zhu
Journal:  Lancet Oncol       Date:  2020-05-13       Impact factor: 41.316

8.  NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121).

Authors:  Mairéad Geraldine McNamara; Lipika Goyal; Mark Doherty; Christoph Springfeld; David Cosgrove; Katrin Marie Sjoquist; Joon Oh Park; Helena Verdaguer; Chiara Braconi; Paul J Ross; Aimery De Gramont; John Raymond Zalcberg; Daniel H Palmer; Juan W Valle; Jennifer J Knox
Journal:  Future Oncol       Date:  2020-05-06       Impact factor: 3.404

9.  Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.

Authors:  T Okusaka; K Nakachi; A Fukutomi; N Mizuno; S Ohkawa; A Funakoshi; M Nagino; S Kondo; S Nagaoka; J Funai; M Koshiji; Y Nambu; J Furuse; M Miyazaki; Y Nimura
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

10.  Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study.

Authors:  Sarah P Blagden; Ivana Rizzuto; Puvan Suppiah; Daniel O'Shea; Markand Patel; Laura Spiers; Ajithkumar Sukumaran; Nishat Bharwani; Andrea Rockall; Hani Gabra; Mona El-Bahrawy; Harpreet Wasan; Robert Leonard; Nagy Habib; Essam Ghazaly
Journal:  Br J Cancer       Date:  2018-09-12       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.